Javascript was detected to be disabled. Javascript is required for some functions on this website.

The Institute for Innovation & Valuation in Health Care, InnoValHC, is an independent not-for-profit research organization. It was established by scientists with medical, health economic, and econometric backgrounds, as well as hands-on management experience, to analyse health economic and treatment strategies (see Profile). Learn more about the institute's Purpose and Projects.

News

Open Letter

Invitation to Stakeholders concerned with Economic Evaluation and Health Technology Assessments (HTAs)

Systematic Health Technology Assessments (HTAs) are increasingly being used to inform policy decisions on the reimbursement of medical interventions. This development represents both opportunities and threats, perception of which may vary depending on vested interests. Naturally, the perspective of payers will be different from that of providers. However, international implementation of HTAs has varied greatly, largely driven by differences in understanding and capturing the "value" offered by health technologies, such as new pharmaceutical products, diagnostic procedures, and medical devices. Given the relevance of this development, please allow me to take this opportunity to draw your attention to this year's Heidelberg Health Economics Summer School.

Read more …

Health Economics Summer School 2015

Heidelberg/Germany, September 14th – September 18th, 2015

The relevance of Health Technology Assessments (HTAs) for market access, pricing and reimbursement of health technologies has in-creased continuously over the last decades. The approaches adopted by HTA agencies to assess “value for money” vary greatly. This variance can hardly surprise as issues related to access to health care represent an area permeated with ideologically charged controversy. Unfortunately, many current courses in health economics do not address the background of this variance.

Thus, the Heidelberg Health Economics Summer School has been established to contribute to closing this gap, addressing the strengths, weaknesses, and potential of alternative economic evaluation para-digms, ranging from cost benefit analysis (CBA) and cost utility / effectiveness analysis (CUA/CEA) to more recently advocated social cost value analysis (CVA). Topical country-specific HTA case studies will be used to illustrate the policy relevance of these concepts, addressing examples such as ultra-orphan drugs, cancer and end-of-life treatments, as well as “personalized medicine”.

The Institute for Innovation & Valuation in Health Care in cooperation with the University of Heidelberg (Department for Public Health, Mannheim Medical Faculty) present a high–level program with these topics:

What are the conceptual foundations and limitations of the current health economic evaluation paradigm?

What are the implications of its actual use in the context of health Technology Assessments (HTAs) and decision-making on market access, pricing and reimbursement of medical technologies?

Read more …